Eledon Pharmaceuticals Inc Ordinary Shares ELDN 深 滬
已收盤 10-31 16:00:00 美东时间
4.32
-0.030
-0.69%
華盛通- 最 高4.45
- 今 開4.36
- 成交量 111.22万股
- 最 低 4.13
- 昨 收 4.35
- 總市值 2.59亿
- 52周最高 5.0826
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.315
- 委 比 60.68%
- 總股本 5988.18万
- 歷史最高 154.98
- 量 比 0.51
- 振 幅 7.36%
- 歷史最低 1.07
- 每 手 1
- 風險率 0.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals announced an oral presentation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting in Houston, TX, featuring Phase 2 BESTOW trial results for tegoprubart in preventing kidney transplant rejection. The presentation, titled "Efficacy and Safety of Tegoprubart," will be delivered by Andrew Adams, M.D., Ph.D., on November 6, 2025, at 5:30 p.m. CT in Grand Ballroom C. Eledon will host a conference call on Nov...
10-17 11:00
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
Eledon Pharmaceuticals' Steve Perrin, Ph.D., will present on anti-CD154 pathway blockade at the 18th Congress of the International Xenotransplantation Association in Geneva on October 1, 2025. The session will focus on advances in immunosuppression and immune monitoring. Eledon is developing tegoprubart, an anti-CD40L antibody, for treating life-threatening conditions such as kidney transplantation, xenotransplantation, and ALS.
09-24 20:05
HC Wainwright & Co. Reiterates Buy on Eledon Pharmaceuticals, Maintains $9 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and maintains $9 price target.
09-02 19:05
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
Eledon Pharmaceuticals' CEO, David-Alexandre C. Gros, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025. The event will be webcast and available for replay on the company's website. Eledon is a biotech company developing immune-modulating therapies, with its lead product, tegoprubart, targeting CD40L for conditions like kidney transplantation and ALS.
08-29 11:00
Eledon Pharmaceuticals Advances in Transplant Trials
Eledon Pharmaceuticals, Inc. ( ($ELDN) ) has released its Q2 earnings. Here is ...
08-19 12:14
Eledon Pharma Q2 EPS $(0.13) Beats $(0.24) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.24) by 46.72 percent. This is a 85.87 percent increase over losses of $(0.92) per share from the
08-15 04:45
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
Eledon Pharmaceuticals reported its 2Q25 financial results and highlighted business progress, including positive data on its immunosuppressive drug tegoprubart in kidney transplantation, which showed stable kidney function with minimal side effects. The company achieved key milestones in kidney, islet cell, and liver allotransplantation, as well as xenotransplantation. Cash reserves stood at $107.6 million as of June 30, 2025, and R&D expenses ro...
08-14 20:20
Voyager Eledon Presents Data From Phase 1b Trial Evaluating Tegoprubart for Prevention Of Rejection In Kidney Transplant Patients
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplantPreliminary iBox data, a key biomarker of kidney function and immunologic
08-07 04:54
美股大行评级 | 潜在涨幅102.43%！Mobileye Global获Canaccord Genuity升目标价至30美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Mobileye Global"买入"评级，目标价从25美元升至30美元；巴克莱：维持TechnipFMC"超配"评级，目标价从45美元升至51美元
07-28 09:33
Craig-Hallum Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Craig-Hallum initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
07-26 01:54
